Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

BACKGROUND: Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdhury, Simon, Bjartell, Anders, Lumen, Nicolaas, Maroto, Pablo, Paiss, Thomas, Gomez-Veiga, Francisco, Birtle, Alison, Kramer, Gero, Kalinka, Ewa, Spaëth, Dominique, Feyerabend, Susan, Matveev, Vsevolod, Lefresne, Florence, Lukac, Martin, Wapenaar, Robert, Costa, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283204/
https://www.ncbi.nlm.nih.gov/pubmed/32500294
http://dx.doi.org/10.1007/s11523-020-00720-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283204/
https://www.ncbi.nlm.nih.gov/pubmed/32500294
http://dx.doi.org/10.1007/s11523-020-00720-2

Ejemplares similares